Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Investments (2016 - 2019)

Historic Long-Term Investments for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q4 2019 value amounting to $19.0 million.

  • Lineage Cell Therapeutics' Long-Term Investments fell 640.39% to $19.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $19.0 million, marking a year-over-year decrease of 640.39%. This contributed to the annual value of $19.0 million for FY2019, which is 640.39% down from last year.
  • According to the latest figures from Q4 2019, Lineage Cell Therapeutics' Long-Term Investments is $19.0 million, which was down 640.39% from $17.7 million recorded in Q3 2019.
  • In the past 5 years, Lineage Cell Therapeutics' Long-Term Investments ranged from a high of $110.8 million in Q3 2017 and a low of $4.4 million during Q1 2016
  • Its 5-year average for Long-Term Investments is $50.6 million, with a median of $43.2 million in 2018.
  • Its Long-Term Investments has fluctuated over the past 5 years, first surged by 204170.41% in 2016, then plummeted by 7024.99% in 2018.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Long-Term Investments stood at $4.7 million in 2015, then skyrocketed by 2041.7% to $100.0 million in 2016, then crashed by 31.79% to $68.2 million in 2017, then plummeted by 70.25% to $20.3 million in 2018, then decreased by 6.4% to $19.0 million in 2019.
  • Its last three reported values are $19.0 million in Q4 2019, $17.7 million for Q3 2019, and $36.5 million during Q2 2019.